Skip to content
Screener

Arbutus Biopharma Corporation ABUS EPS (Diluted)

EPS (Diluted) at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
-$0.93-134%
Gilead Sciences logo
Gilead SciencesGILD
-$8.45-642%
ALN
Alnylam PharmaceuticalsALNY
$1.21+337%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
-$1.84-43.8%
Avalo Therapeutics logo
Avalo TherapeuticsAVTX
-$0.83+56.8%
Assembly Biosciences logo
Assembly BiosciencesASMB
-$0.20+85.0%

Other financials

Income statement

See full
Revenue$1.0M-90.6%
Operating income-$6.0M-501%
Net income-$5.1M-304%

Balance sheet

See full
Cash & equivalents$19.2M-48.8%
Total debt$514.0K-52.8%
Total equity$258.7M+212%
Total assets$274.0M+165%

Cash flow

See full
Operating cash flow-$6.0M+61.8%
CapEx--100%
Free cash flow-$4.7M+55.0%

Valuation

See full
Market cap$903.36M+5.0%
Enterprise value$884.71M+5.4%
P/E5.9×—
P/S5×-53.9×

Profitability

See full
Operating margin82%+44.9pp
Net margin84.2%+46.6pp
FCF margin-281.5%-119pp

Returns & leverage

See full
Return on equity89.6%+65.3pp
Debt / equity0×0.0×
Current ratio81.4×+60.9×

Where this comes from

Reported directly by Arbutus Biopharma Corporation in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Arbutus Biopharma Corporation’s 10-Q, filed August 12, 2026.

Filed
Aug 12, 2026, 7:31 AM EDT
Fiscal quarter
Q3 FY2026
Calendar quarter
Q3 2026
Accession
0001447028-26-000045
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net (loss) income$(5,143)$2,523$164,552$(22,003)
Net (loss) income per common share
Basic$(0.03)$0.01$0.84$(0.12)
Diluted$(0.03)$0.01$0.84$(0.12)
Weighted average number of common shares
Basic197,470,724191,551,282195,626,117191,130,631
Diluted197,470,724192,399,733196,847,687191,130,631
Comprehensive (loss) income

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

FAQ

What is Arbutus Biopharma Corporation's EPS (diluted)?
Arbutus Biopharma Corporation (ABUS) reported EPS (diluted) of -$0.03 in Q2 2026.
How has Arbutus Biopharma Corporation's EPS (diluted) changed year-over-year?
Arbutus Biopharma Corporation's EPS (diluted) decreased by 400.0% year-over-year, from $0.01 to -$0.03.
What is the long-term trend for Arbutus Biopharma Corporation's EPS (diluted)?
Over 4 years (2021 to 2025), Arbutus Biopharma Corporation's EPS (diluted) has grown at a -32.7% compound annual growth rate (CAGR), from -$0.83 to -$0.17.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Arbutus Biopharma Corporation's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude